Canadian Cancer Trials Group Bulletins


Canadian Cancer Trials Group IND Program Expands to Include Pediatrics

The Canadian Cancer Trials Group Investigational New Drug Program plans to extend its drug development program to include the pediatric population.

The IND Program and the Canadian Pediatric Oncology Network, C17, under the respective leaderships of Elizabeth Eisenhauer and Sylvain Baruchel, have worked to develop this initiative, and included this initiative in the Canadian Cancer Trials Group's 5-year grant renewal with CCSRI. The grant was submitted in 2009 and the Canadian Cancer Trials Group underwent a site visit review in February 2010.

The pediatric initiative scored very well and received laudatory comments from reviewers. The initiative has thus begun and will include phase I and early phase II trials of pediatric malignancies.

The initiative's first project is a phase I trial testing SB939, a histone deacetylase inhibitor, in pediatric patients with refractory solid tumours and leukemia.